NAD+ and Sirt5 restore mitochondrial bioenergetics failure and improve locomotor defects caused by sucla2 mutations.

JCI Insight · 2026 · PMC12892911 · PMID 41574612

Europe PMC DOI

hedged sentence

0.0824

closest p · 1.6× alpha

0.0824

boldest claim

The sentences

showed a trendP = 0.0824so close (0.05 < p ≤ 0.1)

Supplementation with NAM/NR from 5 to 10 dpf showed a trend toward improved survival of sucla2 –/– animals ( sucla2 –/– vs. sucla2 –/– + 250 μM NAM/250 μM NR, 14-day time course, treated 4–10 dpf, P = 0.0824) and significant differences of animals alive at 14 dpf ( P = 0.0171) ( Figure 6, E and F ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.